- Home
- SOND vs BCAB Comparison
SOND vs BCAB Comparison
Compare SOND & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOND
- BCAB
- Stock Information
- Founded
- SOND 2014
- BCAB 2007
- Country
- SOND United States
- BCAB United States
- Employees
- SOND N/A
- BCAB N/A
- Industry
- SOND Hotels/Resorts
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- SOND Consumer Discretionary
- BCAB Health Care
- Exchange
- SOND Nasdaq
- BCAB Nasdaq
- Market Cap
- SOND 25.8M
- BCAB 27.0M
- IPO Year
- SOND N/A
- BCAB 2020
- Fundamental
- Price
- SOND $2.11
- BCAB $0.41
- Analyst Decision
- SOND
- BCAB Buy
- Analyst Count
- SOND 0
- BCAB 2
- Target Price
- SOND N/A
- BCAB $1.00
- AVG Volume (30 Days)
- SOND 15.9K
- BCAB 575.6K
- Earning Date
- SOND 05-20-2025
- BCAB 05-06-2025
- Dividend Yield
- SOND N/A
- BCAB N/A
- EPS Growth
- SOND N/A
- BCAB N/A
- EPS
- SOND N/A
- BCAB N/A
- Revenue
- SOND $624,458,000.00
- BCAB $11,000,000.00
- Revenue This Year
- SOND $28.50
- BCAB N/A
- Revenue Next Year
- SOND $17.62
- BCAB N/A
- P/E Ratio
- SOND N/A
- BCAB N/A
- Revenue Growth
- SOND 8.32
- BCAB N/A
- 52 Week Low
- SOND $0.88
- BCAB $0.24
- 52 Week High
- SOND $10.50
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- SOND 43.26
- BCAB 48.12
- Support Level
- SOND $2.13
- BCAB $0.40
- Resistance Level
- SOND $2.38
- BCAB $0.49
- Average True Range (ATR)
- SOND 0.14
- BCAB 0.06
- MACD
- SOND -0.01
- BCAB -0.01
- Stochastic Oscillator
- SOND 9.84
- BCAB 5.43
About SOND Sonder Holdings Inc.
Sonder Holdings Inc is engaged in providing short and long-term accommodations to travelers in various cities across North America, Europe, and the Middle East. The Sonder units in each apartment-style building and each hotel property are selected, designed, and managed directly by the Company. The Company generates revenues by providing short-term or month-to-month accommodations to its guests. The Company also provides accommodations to travelers through boutique hotels.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.